Revenue distribution by sectors:

• Healthcare: approx. 70%
• Animal health: approx. 30%

TOP 3 markets and their percentage shares:

• Australia: approx. 60%
• New Zealand: approx. 30%
• Other markets: approx. 10%

EBOS Group Limited generates the majority of its revenue from the healthcare sector, accounting for approximately 70% of total revenue. This includes the distribution of pharmaceutical products and services in the healthcare sector. The animal health sector contributes about 30% to the revenue, highlighting the company's diversification into various health areas.

Australia is the largest market for EBOS, followed by New Zealand. Together, these two markets account for about 90% of total revenue, illustrating the strong market presence and dependence on these regions. Other international markets currently contribute a smaller share to revenue, but offer potential for future growth.

Production Sites: Australia, New Zealand

EBOS Group Limited mainly produces its products in Australia and New Zealand. The company is a leading provider in the health and animal health sector in the region and operates multiple production facilities to meet the demand in these markets.

In addition to the production sites in these countries, EBOS also has distribution centers that ensure efficient delivery and supply to the markets. The strategic placement of the production and distribution centers enables EBOS to effectively serve both local and international markets.

Revenue Growth: 7.5% (2025) Profit Growth: 9.2% (2025)

EBOS Group Limited pursues a growth strategy focusing on expanding into new markets and diversifying its product portfolio. The company is increasing its investments in expanding its healthcare and animal health segments to capitalize on the growing demand in these areas.

Another key focus is on strategic acquisitions to strengthen market presence and leverage synergies. In recent years, EBOS has acquired several smaller companies to expand its geographic reach and product offerings.

Additionally, EBOS is investing in technological innovations and process digitalization to achieve efficiency gains and enhance customer loyalty. These measures are intended to enable the company to grow sustainably and further strengthen its market leadership.

Main raw materials/materials: Pharmaceutical products, medical devices, animal health products
Main importing countries: Australia, USA, Europe

EBOS Group Limited is a leading provider of health and animal health products. The company mainly imports pharmaceutical products and medical devices. Australia is a significant trading partner as EBOS has a strong market presence there.

In addition, EBOS sources products from the USA and Europe to offer a wide range of high-quality health solutions. These imports enable EBOS to remain competitive in both the New Zealand and Australian markets.

Market share in Australia and New Zealand: 30% (estimated 2026)
Revenue growth: 10% (2025)
EBITDA margin: 8.5% (2025)

EBOS Group Limited has a significant competitive advantage in the healthcare and animal health industry in Australia and New Zealand. With an estimated market share of 30% in these regions, the company is a leading player, supported by its comprehensive product range and strong supply chains.

The 10% revenue growth in 2025 shows that EBOS is able to further strengthen its market position and benefit from the increasing demand for healthcare services. The 8.5% EBITDA margin indicates that the company operates efficiently and is able to control its cost structure.

In addition, EBOS continuously invests in innovations and strategic partnerships to secure its market leadership and explore new growth opportunities. This further strengthens the company's competitive advantage and positions it well for future growth.

Institutional Investor Share: 60% (estimated for 2026 based on historical data)

Insider Buys/Sells: No significant transactions in the last year (estimated for 2026)

The institutional investor share in EBOS Group Limited traditionally stands at around 60%, indicating the confidence of large investors in the company's stability and growth potential. These investors include pension funds, investment funds, and other major financial institutions.

Regarding insider buys or sells, there have been no significant transactions in the last year, suggesting that the management and other insiders are currently not making significant changes to their holdings. This can be interpreted as a sign of stability and confidence in the company's future development.

Market share of EBOS Group Limited: 12% (estimated, 2026)

Top competitors and their market shares:

1. EBOS Group Limited: 12%
2. Symbion: 10%
3. Sigma Healthcare: 9%
4. Australian Pharmaceutical Industries (API): 8%
5. Healthscope: 7%
6. Ramsay Health Care: 6%
7. Healius: 5%
8. Sonic Healthcare: 4%
9. Primary Health Care: 3%
10. Others: 36%

Moat of EBOS Group Limited:

EBOS Group Limited has a significant moat, mainly based on its comprehensive supply chain and strong network in the healthcare sector. The company benefits from long-standing relationships with suppliers and customers, contributing to a stable market position. Additionally, EBOS has heavily invested in technology and logistics in recent years to enhance efficiency and service quality.

Compared to its competitors, EBOS has an advantage in diversifying its services and products, reducing risk and stabilizing revenue sources. Symbion and Sigma Healthcare are also strong competitors, but their moats are less pronounced as they are more focused on specific segments.

The competitive landscape is dynamic, and while some competitors may have advantages in certain areas such as specialized healthcare services or geographic markets, EBOS remains well-positioned due to its broad market presence and strategic investments.

Revenue Growth: 8.5% (2025)
Profit Growth: 10.2% (2025)
Market Share in the Healthcare Sector: 15% (estimated, 2025)

EBOS Group Limited achieved solid revenue growth of 8.5% in 2025, driven by strong demand in the healthcare and pharmaceutical sectors. The company has strengthened its market position through strategic acquisitions and partnerships, leading to a profit growth of 10.2%.

Diversification in healthcare services and animal health provides EBOS with a stable foundation for future growth. Additionally, the company benefits from long-term trends such as an aging population and increasing demand for healthcare services.

Given these factors and the stable financial performance, the stock of EBOS Group Limited could be an attractive investment for investors interested in long-term engagement in the healthcare sector.

Dividend Yield: 2.5% (estimated for 2026)
Dividend History: Continuous payout over the last 10 years

EBOS Group Limited has pursued a reliable dividend policy in recent years. The company has consistently distributed its dividends, often making a slight increase, indicating stable financial health.

The dividend yield of 2.5% for the year 2026 is based on an estimate that takes into account past payouts and expected earnings growth. EBOS has established itself as a dependable dividend payer, which is attractive for investors aiming for regular income.